

Ramaprasad Srinivasan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666085/publications.pdf>

Version: 2024-02-01

40
papers

2,257
citations

516710

16
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

3947
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
2	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. Journal of Urology, 2007, 177, 2074-2080.	0.4	235
3	Molecular genetics and cellular features of TFE3 and TFE3 fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	3.8	227
4	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. Cancer Cell, 2011, 20, 315-327.	16.8	190
5	The Metabolic Basis of Kidney Cancer. Cancer Discovery, 2019, 9, 1006-1021.	9.4	163
6	UOK 262 cell line, fumarate hydratase deficient (FH ^{-/-} /FH ^{-/-}) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genetics and Cytogenetics, 2010, 196, 45-55.	1.0	131
7	Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. British Journal of Haematology, 2006, 133, 305-314.	2.5	102
8	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clinical Cancer Research, 2015, 21, 10-17.	7.0	88
9	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	16.8	87
10	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. Cancer Research, 2016, 76, 2177-2185.	0.9	86
11	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. Science Signaling, 2021, 14, .	3.6	64
12	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. Journal of Clinical Oncology, 2020, 38, 5004-5004.	1.6	53
13	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. Journal of Clinical Oncology, 2020, 38, 1146-1153.	1.6	39
14	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	1.9	36
15	SnapShot: Renal Cell Carcinoma. Cancer Cell, 2016, 29, 610-610.e1.	16.8	35
16	Comprehensive genomic and phenotypic characterization of germline <i>FH</i> deletion in hereditary leiomyomatosis and renal cell carcinoma. Genes Chromosomes and Cancer, 2017, 56, 484-492.	2.8	21
17	Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial. Clinical Cancer Research, 2022, 28, 1540-1548.	7.0	21
18	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. Journal of Cancer, 2020, 11, 3596-3603.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. <i>Current Opinion in Oncology</i> , 2020, 32, 240-249.	2.4	15
20	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	7.0	13
21	Anti-angiogenic therapy in renal cell cancer. <i>BJU International</i> , 2007, 99, 1296-1300.	2.5	12
22	Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion. <i>BMC Cancer</i> , 2019, 19, 917.	2.6	12
23	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	4.1	11
24	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020, 68, 14-19.	1.5	10
25	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 434-446.	2.8	10
26	Therapeutic Strategies for Hereditary Kidney Cancer. <i>Current Oncology Reports</i> , 2016, 18, 50.	4.0	9
27	Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 114.e9-114.e14.	1.6	7
28	A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 212-220.	2.4	6
29	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2019, 27, 100922.	0.3	5
30	Kidney cancer: from genes to therapy. <i>Current Problems in Cancer</i> , 2021, 45, 100773.	2.0	5
31	Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 220-225.	3.8	4
32	¹⁸ F-fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021, 46, 3301-3308.	2.1	4
33	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	4
34	Challenging and refining treatment paradigms. <i>Nature Reviews Urology</i> , 2018, 15, 77-78.	3.8	3
35	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4584-4584.	1.6	3
36	Clinical evaluation of 2-(¹⁸ F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 383-383.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Antiangiogenic therapy in renal cell carcinoma: from concept to reality. Nature Reviews Urology, 2007, 4, 74-75.	1.4	2
38	Predictors of mortality in metastatic papillary renal cell cancer.. Journal of Clinical Oncology, 2017, 35, 509-509.	1.6	1
39	Nephrotic syndrome following non-myeloablative stem cell transplantation - Response to Ruiz-Arguelles and Gomez-Almaguer. British Journal of Haematology, 2006, 132, 802-803.	2.5	0
40	Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors. , 0, , 958-959.		0